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 Leukocytapheresis (LCAP) was performed in seven pa-
tients with moderate or severe active ulcerative colitis (UC) 
at the Koga Hospital. LCAP was considered as having been 
effective in all seven patients (excellent clinical response in 
five and moderate clinical response in two patients). The 
excellent or moderate clinical response continued through-
out maintenance LCAP in three of seven patients. None of 
the patients required discontinuation of LCAP, despite the 
appearance of some side effects, including facial redness, 
low-grade fever, discomfort, headache and hypotension dur-
ing the therapy. The results of this study indicate that 
LCAP may be a safe and effective intensive and mainte-
nance therapy for UC. 
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leukocyte removal filter or centrifugal method (7-10). 
In our hospital, LCAP was performed in seven pa-
tients with severe UC, and in this report we present 
the effects of this therapy.
Patients and Methods
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Introduction
 Corticosteroids are effective for inducing clinical re-
mission in patients with ulcerative colitis (UC) (1,2). 
However, in severely relapsed cases, corticosteroids are 
not always effective, even when a high dosage is ad-
ministered (3,4). In addition, the long-term use of 
corticosteroids often causes serious side effects, includ-
ing hormonal derangements, peptic ulcers and psycho-
logical problems (5,6). Therefore, an alternative treat-
ment for active ulcerative colitis is desirable in order 
to avoid these clinical problems. 
 Recently, the efficacy of leukocytapheresis (LCAP) 
was reported for inflammatory bowel disease, using a
 LCAP was performed in seven patients with UC 
(four males and three females) between November 
1995 and June 1998 in Koga Hospital. Three patients 
had moderate active UC and four had severe active 
UC, and showed insufficient response to conventional 
therapy. Informed consent was obtained from all pa-
tients prior to inclusion in the study. Table 1 provides 
the clinical profile of the participating patients. Imugard 
(Terumo Corporation, Tokyo, Japan) was used as a 
leukocyte removal filter (Fig. 1 A,B). Heparin or 
nafamostat mesilate was used as anticoagulant and 
1575 ml of whole blood were processed with a blood 
flow rate of 35 ml/min for each procedure for a dura-
tion of 45 min. 
 LCAP was usually performed once each week for 
five weeks in severely affected UC patients requiring 
intensive therapy. For maintenance therapy, LCAP 
was usually performed once every four to six weeks 
until steroids were discontinued or the dose tapered, 
or for up to six months. LCAP was discontinued and 
the clinical course of the patient was followed after 
steroids were discontinued or tapered to a mainte-
nance dose of 5-10 mg. For the evaluation, we classi-
fied the response to the LCAP using the criteria of 
Egashira et al. (11); excellent, moderately improved, no 
change, or deterioration.
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Table 1. Demography of patients with ulcerative colitis 
treated by LCAP
Age (mean ± SEM) 51.4 ± 12.3 
Male/Female 4/3 
Duration of disease (years) 5.5 ± 3.5 
Severity of UC 
    severe 4 
    moderate 3
   pancolitis 5
   left-side colitis 2 
Types of clinical course 
   one only attack type 1 
    relapse-remitting type 4
   chronic persistent type 2
Resul
 All patients included in the study had active UC 
(pancolitis [n=5], left-side colitis [n=2]). Six (87.5%) of 
the seven patients achieved clinical remission within 
four weeks of undergoing apheresis, and remained in 
remission for an average of eight months without any 
additional corticosteroid therapy. As intensive therapy, 
LCAP was effective in all seven patients (excellent 
[n=5] and moderately effective [n=2]; effectiveness rate 
= 100%). Maintenance LCAP was also effective in three 
patients, who progressed to a remission stage (Table 
2). Side effects, such as facial redness, low grade fever, 
discomfort and headache occurred in some cases, but 
none of the patients required discontinuation of LCAP 
(Table 3). Blood biochemical parameters did not change 
significantly between before and after LCAP. No ef-
Table 2. Effectiveness of LCAP.
Data are number of patients
A. Intensive therapy n (%) 
     excellent clinical response 5(71.4) 
     moderate clinical response 2(28.6) 
     no clinical response 0(0) 
     change for the worse 0(0) 
B. Maintenance therapy 
     continuousremission 3(100) 
     change for the worse 0(0)
Table 3. Side effects of LCAP
Figure 1. Imugard leukocyte removal filter before (A) and 
after (B) LCAP.
     Side effect n (%) 





Abdominal pain 1 (14.3) 
Arthralgia 1(14.3) 
Nausea, vomiting 1(14.3)
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fects of the therapy were noted on hepatic or renal 
function.
Case
 A 41-year-old male was admitted to our hospital in 
April, 1998 with a history of melena. On admission, he 
had bloody stools 5-6 times/day, abdominal pain, 
slight fever and hypoproteinemia. Prior to admission, 
the condition had not improved for about nine
months, despite various drug therapies. Physical ex-
amination on admission revealed mild tenderness of 
the left lower abdomen. Laboratory studies showed 
moderate anemia (hemoglobin 9.8 g/dl) and an ele-
vated CRP (15.0 mg/dl). Colonoscopy showed hypere-
mia, oozing of blood, and diffuse mucosal ulcerations. 
The diagnosis was established as severe pancolitis 
(Fig. 2A). After admission, IVH and steroid therapy 
(40 mg methylprednisolone) was performed for two 
weeks, but both were ineffective. LCAP was per-
formed once a week for five courses. The patient be-
came asymptomatic after two LCAP courses, and labo-
ratory data reverted to within normal limits after five 
LCAP treatments. Colonoscopy after LCAP confirmed 




Figure 2. Endoscopic appearance of the sigmoid colon. A. 
Colonoscopy on admission revealed hyperemia, oozing of 
blood, and diffuse mucosal ulceration. B. Colonoscopy after 
five LCAP treatments revealed almost normal mucosa with-
out ulceration.
 Ulcerative colitis is characterized by infiltration of 
inflammatory cells such as monocytes, lymphocytes 
and neutrophils. Immune effector mechanisms are cen-
tral to the disease process in inflammatory bowel dis-
ease, but it is not clear whether the mucosal or sys-
temic immunological abnormalities are primary 
phenomena, or are secondary to disease activity (12). 
Activated neutrophils, as well as lymphocytes, are 
thought to play an important role in the pathogenesis 
of UC. The exact mechanism by which LCAP reduces 
severe colonic inflammation in active UC is obscure. 
One possible mechanism using the Imugard filter may 
be the removal of leukocytes. About 70% of leukocytes 
are removed in a single pass through this filter, and 3 
x 109 leukocytes are calculated to be removed in a 
single procedure (13). A few reports have suggested 
that in cases where LCAP is effective, production of 
pro-inflammatory cytokines, such as interleukin (IL)-1, 
IL-6, IL-8 and tumor necrosis factor (TNF)-a, de-
creased, whereas this did not occur in cases where 
treatment was ineffective (14,15). 
 LCAP is reported to be beneficial in other diseases, 
including rheumatoid arthritis, erythroderma, and 
Crohn's disease, in which it can halt the "vicious im-
mune cycle" and relieve local inflammation (16-18). 
One report, based on flow cytometric analysis stated 
that among UC patients with repeated recurrences, 
LCAP tended to be effective in those with elevated ac-
tivated leukocyte counts, but not in those with low 
counts with minimal active inflammation (7). Since 
our study included only patients with severe and ac-
tive UC, the effect of LCAP in patients with mild UC 
could not be determined. This is probably because of 
repeated recurrences and progression to chronic UC,
with secondary activation of leukocytes and trigger-
ing of the so-called "vicious immune cycle" (9). 
 LCAP had a dramatic effect in many cases in an un-
controlled study, although clinical evaluation was per-
formed as early as just before the fourth treatment (9). 
Sawada et al. (19) proposed that the major inclusion 
criterion for LCAP therapy was insufficient response 
to conventional drug therapy, and that LCAP could be 
a treatment for UC that falls between drug therapies 
and surgery. The results of the present study indicate 
that LCAP may be useful as a therapy both in acute 
disease and during maintenance. However, no definite 
consensus has been reached with regard to the re-
quired duration of therapy. Several issues remain un-
resolved, including whether permanent or semi-
permanent LCAP is required to maintain remission, 
and the optimum duration of LCAP therapy. In our 
hospital, LCAP is usually performed once every four 
to six weeks until steroids are discontinued or their 
dose tapered, or for up to six months. LCAP is discon-
tinued and the clinical course of the patient is fol-
lowed when steroids are discontinued or tapered to a 
maintenance dose of 5-10 mg. To date, there are no 
reports of recurrence of UC in any patient during or 
after LCAP. However, the follow-up period in our 
study is only 12 months at most, and longer follow-up 
will be necessary in future studies. 
 With respect to safety, none of the patients required 
discontinuation of LCAP, despite the appearance of 
side effects during therapy; LCAP had to be discontin-
ued prematurely in two patients due to the develop-
ment of severe malaise. LCAP may have serious side 
effects such as hypotension in patients who are in 
poor general condition (19,20). It would be prudent to 
avoid LCAP in patients in poor general condition, pa-
tients with a systolic blood pressure of 80 mmHg or 
lower, patients under 10 or over 75 years of age, pa-
tients with serious hepatic or renal disorders, and pa-
tients with bleeding tendencies (19). 
  In conclusion, LCAP therapy is useful for patients 
with severe attacks of ulcerative colitis, including 
those who fail to respond to glucocorticoid therapy.
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